Cargando…

Biomarkers for Monitoring Renal Damage Due to Fabry Disease in Patients Treated with Migalastat: A Review for Nephrologists

Nephropathy is a major Fabry disease complication. Kidney biopsies reveal glomerulosclerosis even in pediatric patients. The main manifestations of Fabry nephropathy include reduced glomerular filtration rate and proteinuria. In 2016, an oral pharmacological Chaperone was approved to treat Fabry pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jaurretche, Sebastián, Conde, Hernan, Gonzalez Schain, Ana, Ruiz, Franco, Sgro, Maria Victoria, Venera, Graciela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601519/ https://www.ncbi.nlm.nih.gov/pubmed/36292636 http://dx.doi.org/10.3390/genes13101751

Ejemplares similares

Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?
por: Perretta, Fernando, et al.
Publicado: (2023)

Migalastat: A Review in Fabry Disease
por: McCafferty, Emma H., et al.
Publicado: (2019)

Variables Associated with a Urinary MicroRNAs Excretion Profile Indicative of Renal Fibrosis in Fabry Disease Patients
por: Jaurretche, Sebastián, et al.
Publicado: (2019)

Correction to: Migalastat: A Review in Fabry Disease
por: McCafferty, Emma H., et al.
Publicado: (2019)

In Vitro and In Vivo Amenability to Migalastat in Fabry Disease
por: Lenders, Malte, et al.
Publicado: (2020)

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
por: Benjamin, Elfrida R., et al.
Publicado: (2017)

Long-term follow-up of renal function in patients treated with migalastat for Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2021)

High Lyso-Gb3 Plasma Levels Associated with Decreased miR-29 and miR-200 Urinary Excretion in Young Non-Albuminuric Male Patient with Classic Fabry Disease
por: Jaurretche, Sebastián, et al.
Publicado: (2019)

Medication adherence in Fabry patients treated with migalastat: Real world experience
por: Riccio, Eleonora, et al.
Publicado: (2023)

Early Renal Involvement in a Girl with Classic Fabry Disease
por: Perretta, Fernando, et al.
Publicado: (2017)

Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
por: Young-Gqamana, Brandy, et al.
Publicado: (2013)

Pregnancy Outcome after Exposure to Migalastat for Fabry Disease: A Clinical Report
por: Haninger-Vacariu, Natalja, et al.
Publicado: (2019)

Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

Long-Term Monitoring of Cardiac Involvement under Migalastat Treatment Using Magnetic Resonance Tomography in Fabry Disease
por: Gatterer, Constantin, et al.
Publicado: (2023)

Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes
por: Hughes, Derralynn A, et al.
Publicado: (2023)

The migalastat GLP-HEK assay is the gold standard for determining amenability in patients with Fabry disease
por: Schiffmann, Raphael, et al.
Publicado: (2019)

Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study
por: Bichet, Daniel G., et al.
Publicado: (2023)

Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease
por: Pogoda, Christian, et al.
Publicado: (2023)

Response to “Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real‐World Data”
por: Müntze, Jonas, et al.
Publicado: (2019)

Major Organic Involvement in Women with Fabry Disease in Argentina
por: Perretta, Fernando, et al.
Publicado: (2018)

Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial
por: Schiffmann, Raphael, et al.
Publicado: (2018)

Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
por: Riccio, Eleonora, et al.
Publicado: (2020)

Migalastat Treatment in a Kidney-Transplanted Patient with Fabry Disease and N215S Mutation: The First Case Report
por: Di Stefano, Valeria, et al.
Publicado: (2021)

Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
por: Müntze, Jonas, et al.
Publicado: (2019)

Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study
por: Hughes, Derralynn A., et al.
Publicado: (2019)

Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study
por: Germain, Dominique P., et al.
Publicado: (2019)

Prevalence of chronic kidney disease in fabry disease patients: Multicenter cross sectional study in Argentina
por: Jaurretche, Sebastián, et al.
Publicado: (2017)

Direct Correlation between Age at Diagnosis and Severity of Nephropathy in Fabry Disease Patients
por: Jaurretche, Sebastián P. A., et al.
Publicado: (2019)

Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
por: Mauer, Michael, et al.
Publicado: (2017)

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
por: Hughes, Derralynn A, et al.
Publicado: (2017)

Renal transplant ultrasound: The nephrologist's perspective
por: Leong, Khai Gene, et al.
Publicado: (2015)

Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase
por: Warnock, David G., et al.
Publicado: (2015)

Correction: Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
Publicado: (2018)

Treatment of multiple myeloma with renal involvement: the nephrologist’s view
por: Favà, Alexandre, et al.
Publicado: (2018)

Role of pediatric nephrologists in managing adults with AKI due to COVID-19
por: Lipton, Marissa, et al.
Publicado: (2020)

Presentation of the Child with Renal Disease and Guidelines for Referral to the Pediatric Nephrologist
por: Barakat, Amin J.
Publicado: (2012)

Knowledge, attitude, and practice of nephrologists on the decision for renal replacement therapy
por: Hu, Xiaofang, et al.
Publicado: (2023)

Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study
por: Narita, Ichiei, et al.
Publicado: (2019)

Local anesthetics for the Nephrologist
por: Uppal, Nupur N, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4vc1aaob9igkmuhun59e07mdil